Who are the leading contract research organizations for running oncology clinical trials in Eastern Europe?

If you mean CROs that can actually execute oncology trials across Central/Eastern Europe (CEE)—site selection, feasibility, regulatory/start-up, monitoring, recruitment, data management, etc.—I’d put the following on the shortlist.

Leading choices

My practical shortlist

If I were selecting a CRO for an oncology program today, I'd probably invite 6–7 CROs to bid:

For a large multinational Phase III:
IQVIA, ICON, PPD/Thermo Fisher, Parexel, Medpace

For a biotech-sponsored Phase II/III with a strong CEE component:
Medpace, PSI, HungaroTrial, Research Professionals, plus one of IQVIA/ICON/PPD for comparison.

The distinction is important: the biggest CRO isn't automatically the best CRO for Eastern Europe. A regional CRO can sometimes have substantially better investigator relationships, recruitment knowledge, and hands-on site management in Poland, Romania, Hungary, Czechia, Bulgaria, Serbia, etc.

Why CEE is attractive for oncology

Poland, Hungary and the Czech Republic are particularly established clinical-trial markets, with experienced sites and substantial Phase II/III activity. ccrps.org For oncology specifically, I'd pay close attention to the CRO's actual investigator network by tumor type, rather than simply its overall country footprint.

Recent European CTIS data reinforce the dominance of the big CROs: across 887 oncology Phase III trials authorized in 2024–2026, 49.9% had identifiable CRO/vendor support, with IQVIA, ICON/PRA, PPD/Thermo Fisher and Parexel leading the named providers.

What I'd evaluate before choosing

For an oncology study, I would ask each CRO for:

1. Number of oncology sites actually activated in each target CEE country over the last 3 years.
2. Recruitment performance by tumor type—not generic country-level recruitment statistics.
3. Named investigators/PIs they propose for your indication.
4. Historical screen-failure and enrollment rates at those sites.
5. Regulatory/start-up timelines under EU CTR/CTIS.
6. CRA and CTM turnover on comparable oncology studies.
7. Whether monitoring and study management are locally staffed or centralized elsewhere.
8. Examples of comparable oncology trials they have recently run in Poland/Romania/Hungary/Czechia.
9. Their approach to rescue sites when recruitment falls behind.
10. A country-by-country budget—not just the blended European CRO rate.

One important point: if you tell me the cancer indication, phase, approximate patient count, and which Eastern European countries you're considering, I can narrow this to the top 5 CROs specifically for that trial and compare their CEE footprint, oncology experience, likely recruitment strengths, and relative positioning.

Central and Eastern Europe (CEE) is a major global hub for oncology clinical trials, driven by large treatment-naïve patient populations, highly experienced medical investigators, and robust centralized hospital infrastructures.

The leading contract research organizations (CROs) specializing in or heavily featuring operations in this region for oncology trials range from prominent regional specialists to global giants with deep CEE footprints:

Prominent Regional and Specialist CROs

• OCT Clinical stands as one of the largest independent regional CROs explicitly focused on Eastern Europe and the CIS countries, managing comprehensive Phase I–IV trials with core therapeutic strength in oncology.
• Cromos Pharma is an international CRO with deep, long-standing operational expertise across Central and Eastern Europe, the Caucasus, and Central Asia, frequently noted for its strong site networks and high patient recruitment velocity in oncology fields (particularly in hubs like Poland).
• Atlan Clinical operates as a prominent regional provider scaling across Eastern Europe and neighboring areas, recognized for managing complex oncology and hematology portfolios with localized regulatory expertise.
• BiTrial Clinical Research specializes across Central and Eastern Europe (including the Czech Republic, Hungary, Bulgaria, and Croatia), offering full-service clinical operations with a patient-centric framework.
• KCR (part of ICON plc) has decades of specialized mid-sized operational experience rooted strongly in Central and Eastern Europe, offering dedicated execution in oncology and rare diseases.

Global/Multinational CROs with Strong Regional Footprints

• Novotech (incorporating regional acquisition EastHORN) delivers extensive early-to-late-phase clinical services across Europe, combining global reach with localized Eastern European site navigation.
• Global Tier-1 CROs such as IQVIA, Parexel , and ICON plc maintain extensive, embedded operational footprints throughout CEE core countries—especially Poland, which serves as the region's blueprint and primary engine for oncology recruitment.

If you'd like to narrow this down, please let me know:

• Are you looking for a niche regional specialist or a global top-tier CRO?
• Which specific countries in Eastern Europe (e.g., Poland, Czech Republic, Baltic states, or southeastern Europe) are you targeting?

Central and Eastern Europe (CEE) has become a prominent hub for oncology clinical trials due to its large, treatment-naive patient pools , well-established academic medical infrastructure, and cost-efficient operations.

Leading contract research organizations (CROs) operating in this region range from specialized regional experts to major global players with deep local footprints:

• OCT Clinical (incorporating Palleos Healthcare) — Recognized as a leading regional full-service CRO in Eastern Europe and the CIS/CEE countries. They feature a dedicated OCT Oncology division with an extensive proprietary network spanning hundreds of specialized oncology clinics across multiple Eastern European countries.
• Cromos Pharma — An international CRO with an intense operational focus and deep-rooted infrastructure across Central and Eastern Europe. They have extensive experience managing complex Phase I-IV oncology, biosimilar, and rare disease programs, heavily leveraging regional recruitment dynamics in countries like Poland and Bulgaria.
• Sofpromed — A full-service European CRO with robust clinical trial monitoring and site management capabilities specifically active in oncology throughout Poland, the Czech Republic, Slovakia, and other Eastern European regions.
• Precision For Medicine (incorporating Argint International) — Strengthened significantly by its acquisition of Argint, Precision maintains a major operational footprint across Hungary, Poland, Romania, Serbia, and Slovakia, specializing in expediting complex multi-regional oncology and specialty trials.
• Comac Medical — A prominent regional full-service CRO with over 27 years of experience managing trials across Central and Eastern Europe (including Poland, Bulgaria, Romania, Hungary, and the Czech Republic), with strong capabilities in oncology development.
• ICON plc (incorporating KCR) — As a top-tier global CRO, ICON enhanced its specialized Central and Eastern European footprint and biotech-focused oncology service offerings through strategic regional acquisitions like KCR.
• Syneos Health & Worldwide Clinical Trials — Major global CROs that actively accelerate and expand their operational networks across Eastern Europe (such as Worldwide's strategic hub in Warsaw, Poland) to leverage lower-cost sites, robust investigator relationships, and large patient populations for Phase I-IV oncology programs.

If you'd like to narrow this down, please let me know:

• Are you looking for a regional specialist or a global mega-CRO?
• Which specific Eastern European countries (e.g., Poland, Bulgaria, Czech Republic, Hungary) are you targeting?
• What Phase is your oncology trial in?

For oncology clinical trials in Eastern Europe (CEE: Poland, Czech Republic, Hungary, Romania, Bulgaria, Serbia, Ukraine, Slovakia, Baltics, etc.), the leading CROs are generally a mix of large global full-service CROs and regionally strong specialists. The “best” choice depends on whether you need Phase I oncology expertise, rapid site activation, rare tumor recruitment, regulatory support, or cost-efficient multi-country execution.

Leading CROs for oncology trials in Eastern Europe

Industry analyses of European oncology Phase III outsourcing show the largest CRO groups appearing most frequently include IQVIA, ICON/PRA, Clario/Bioclinica/ERT, PPD/Thermo Fisher, and Parexel.

CROs with particularly strong Eastern European positioning

PSI CRO

Often considered one of the strongest “CEE-native” CRO choices. PSI built much of its reputation around Eastern European investigator networks and has extensive oncology experience. It is frequently shortlisted when sponsors want:

• faster site start-up,
• experienced oncology investigators,
• strong CRA coverage,
• competitive cost structures.

IQVIA

A common choice for multinational oncology programs because it can combine:

• local CEE execution,
• global regulatory strategy,
• centralized data capabilities,
• companion diagnostics and biomarker support.

IQVIA was among the most frequently represented CROs in recent European oncology Phase III trial analyses.

ICON plc

Strong for:

• large Phase III oncology,
• global enrollment,
• complex operational models,
• oncology programs requiring many countries.

ICON/PRA ranked among the most frequently used CRO groups in European oncology Phase III trials.

Country-specific considerations

• Poland – often the largest CEE recruitment market; strong oncology centers and broad patient access.
• Czech Republic & Hungary – mature clinical trial infrastructure, experienced investigators.
• Romania & Bulgaria – attractive for recruitment speed and cost efficiency, though site selection is important.
• Serbia – frequently used for oncology recruitment because of experienced investigators and efficient execution.
• Ukraine – historically strong in oncology trials, but operational risk has increased due to the war.

Typical shortlist by sponsor type

Large pharma Phase III oncology

1. IQVIA
2. ICON/PRA
3. PPD/Thermo Fisher
4. Parexel

Biotech oncology (Phase I–II, immunotherapy, targeted agents)

1. PSI CRO
2. Medpace
3. Parexel
4. Worldwide Clinical Trials

Cost-sensitive CEE-focused oncology trial

1. PSI CRO
2. TFS HealthScience
3. Medpace
4. Regional CRO partners combined with a global CRO

What I would evaluate before selecting a CRO

For Eastern European oncology specifically, I would compare:

• number of active oncology sites in Poland/Czechia/Hungary/Romania/Serbia,
• median site activation timelines,
• prior enrollment in the exact tumor type,
• CRA turnover in CEE,
• biomarker/central lab capabilities,
• experience with EMA/CTIS submissions,
• patient recruitment forecasting accuracy.

If you are selecting a CRO for a specific oncology phase (I, II, III), tumor type (solid tumor, hematology, rare cancer), and countries, the ranking can change significantly.

If you're selecting a CRO for oncology trials in Central and Eastern Europe (CEE), it's helpful to distinguish between:

• Global CROs with deep oncology practices and extensive CEE operations.
• Regional specialist CROs whose competitive advantage is investigator relationships, patient recruitment, and regulatory execution across Eastern Europe.

Tier 1: Global CROs with strong Eastern European oncology capabilities

These organizations run many of the largest multinational oncology studies and have established operational networks across Poland, Czech Republic, Hungary, Romania, Bulgaria, Slovakia, Serbia, and neighboring countries.

These firms are typically preferred for:

• Global Phase II–III oncology programs
• Registration studies
• Complex biomarker-driven trials
• Large multinational protocols

---

Leading regional CROs focused on Central & Eastern Europe

These companies often provide better local execution than larger global CROs, especially when enrollment in CEE is a major objective.

HungaroTrial

One of the best-known independent regional CROs.

Strengths:

• Active across 20+ CEE countries
• Long operating history (since 1999)
• Strong patient recruitment
• Deep investigator relationships
• Significant oncology experience alongside other therapeutic areas

Best suited for:

• Regional CEE studies
• Rescue recruitment
• Mid-size biotech programs

---

OCT Clinical

A long-established Eastern European CRO that recently merged with Palleos Healthcare to broaden its European footprint.

Strengths:

• Hundreds of studies conducted in CEE and CIS
• Explicit therapeutic focus in oncology
• Full-service capabilities from startup through biostatistics and medical writing

Best suited for:

• Oncology-focused regional studies
• Sponsors wanting strong Eastern European operational expertise

---

Cromos Pharma

Known for strong execution in Poland and neighboring countries.

Strengths:

• Oncology emphasis
• Poland regarded as a major recruitment market
• Good regional regulatory expertise

---

CROS CRO

A smaller full-service CRO with growing CEE operations.

Strengths:

• Phase I–IV studies
• Site startup
• Feasibility
• Clinical operations
• Investigator network development

Often attractive for:

• Early-stage biotech
• Smaller oncology studies
• Flexible service models

---

Countries that consistently perform well for oncology enrollment

Among CEE countries, these are generally considered the strongest oncology markets:

• Poland — Europe's largest oncology recruitment market in CEE with many experienced cancer centers.
• Czech Republic — Strong academic oncology institutions and efficient startup timelines.
• Hungary — High-quality investigators and centralized healthcare infrastructure.
• Romania — Good recruitment potential for certain tumor types.
• Bulgaria — Frequently included in multinational oncology studies because of strong enrollment performance.

Which CRO is the best fit?

That depends on the sponsor and study:

• Large pharmaceutical company, global Phase III: IQVIA, ICON, Parexel, or PPD are usually the leading choices.
• Mid-size biotech expanding into Europe: OCT Clinical or HungaroTrial often offer a strong balance of regional expertise and operational flexibility.
• Enrollment-heavy CEE strategy: HungaroTrial and OCT Clinical are particularly well regarded for local investigator relationships and recruitment.
• Single-country or Poland-focused oncology study: Cromos Pharma can be a strong regional option.

For an oncology trial where Eastern Europe is expected to contribute 30–70% of patient enrollment, many sponsors use a hybrid model: a global CRO (such as IQVIA or ICON) serves as lead CRO while a specialized regional partner (such as HungaroTrial or OCT Clinical) manages local operations and site relationships in CEE. This can combine global oversight with strong regional execution.

Running oncology clinical trials in Central and Eastern Europe (CEE) requires navigating localized site networks, robust patient pools, and country-specific regulatory pathways . Leading contract research organizations (CROs) active in this region range from specialized regional experts to dominant global players with heavy local footprints.

Dedicated Regional and Mid-Sized CROs in Eastern/Central Europe

• OCT Clinical : A prominent full-service regional leader with deep roots across Eastern Europe, specializing heavily in oncology trials through an extensive proprietary network of regional cancer centers and clinics.
• Cromos Pharma : An international CRO with extensive operational capabilities and deep in-country infrastructure across Central and Eastern Europe, widely recognized for high patient recruitment yields and flexible risk-sharing frameworks in oncology.
• Optimapharm : A leading regional full-service CRO providing strong clinical trial execution across Eastern and South-Eastern Europe, noted for high repeat business rates from international sponsors.
• Precision European CRO Services (formerly Argint International) : Specializes tightly in Central and Southeastern Europe (including Poland, Hungary, Serbia, and Romania), offering streamlined regulatory navigation and rapid patient access for oncology.

Global Tier-1 CROs with Robust Eastern European Networks

• IQVIA : As the world's largest global CRO, IQVIA maintains massive operational infrastructure, dedicated therapeutic oncology teams, and deep site penetration across major CEE clinical trial hubs like Poland and the Czech Republic.
• ICON plc : ICON possesses a dominant European presence—further amplified by strategic acquisitions integrating regional powerhouses—making them a primary choice for large-scale, multi-regional oncology programs touching Eastern Europe.
• Parexel : Features dedicated regional offices (such as in Poland) and deep global oncology leadership, pairing ex-agency regulatory guidance with expansive site networks throughout the region.

If you can share the specific phase of your trial, the exact cancer indication , or which countries in Eastern Europe you are targeting, I can help narrow down whether a regional niche CRO or a global enterprise is the better fit.

If you're evaluating CROs specifically for oncology clinical trials in Central and Eastern Europe (CEE), the strongest options fall into two broad groups:

1. Global CROs with extensive oncology capabilities and established CEE operations.
2. Regional CROs whose competitive advantage is deep local investigator networks, regulatory expertise, and patient recruitment across Eastern Europe.

Here's a practical overview.

Global leaders

These organizations consistently manage many multinational oncology trials and have dedicated oncology business units.

• IQVIA

  • Probably the strongest combination of oncology expertise, data capabilities, and investigator relationships.
  • Extensive operations in Poland, Czech Republic, Hungary, Romania, Bulgaria, the Baltics, and other CEE countries.
  • Particularly strong for biomarker-driven and precision oncology studies.

• ICON

  • One of the world's largest oncology CROs.
  • Strong experience in solid tumors, hematology, immuno-oncology, and rare cancers.
  • Long-established monitoring and project management teams throughout Eastern Europe.

• Parexel

  • Frequently selected for complex oncology development programs.
  • Particularly strong regulatory and medical affairs support.
  • Good relationships with leading academic cancer centers.

• PPD (Thermo Fisher Scientific)

  • Extensive experience supporting pivotal oncology registration trials.
  • Large CRA network across Europe.

Recent analyses of European oncology trials continue to identify IQVIA, ICON, Parexel, and PPD among the most frequently involved CROs in multinational oncology programs.

Regional specialists

If your study will recruit heavily from Central and Eastern Europe, regional CROs can sometimes outperform global firms on enrollment speed and local execution.

Optimapharm (Croatia)

Advantages include:

• operations across more than 30 countries
• strong CEE CRA network
• competitive pricing
• good reputation with mid-sized biotech companies

It has grown into one of the largest CROs headquartered in Central and Eastern Europe.

OCT Clinical

A particularly well-known regional CRO that focuses on Eastern Europe.

Strengths include:

• oncology as a core therapeutic area
• extensive investigator relationships
• experience across Poland, Romania, Bulgaria, the Baltics, and neighboring countries
• full-service Phase I–IV capabilities

OCT has conducted hundreds of clinical trials in Eastern Europe and positions oncology as one of its major therapeutic specialties.

Cromos Pharma

Known for:

• Poland
• Ukraine (where feasible)
• Georgia
• Moldova
• other Eastern European markets

The company has highlighted Poland as an increasingly important oncology recruitment market because of strong patient access, experienced investigators, and EU regulatory alignment.

Countries with particularly strong oncology recruitment

Within Eastern Europe, these countries are often prioritized:

• Poland – arguably the strongest oncology research market in CEE
• Czech Republic
• Hungary
• Romania
• Bulgaria
• Slovakia
• Lithuania
• Latvia
• Estonia

These countries generally offer:

• experienced oncology investigators
• high-quality academic cancer centers
• faster enrollment than many Western European markets
• lower operating costs
• harmonized EU regulatory pathways (for EU member states)

How sponsors typically choose

For a large Phase III registration study:

• IQVIA
• ICON
• Parexel
• PPD

For a mid-sized biotech with budget constraints:

• Optimapharm
• OCT Clinical
• Cromos Pharma (depending on geography)

For a hybrid model:

• Global CRO as the prime contractor
• Regional CRO as a preferred partner or local service provider in CEE

This approach can improve recruitment while maintaining global oversight.

Selection criteria beyond reputation

When comparing proposals, sponsors often focus on:

• oncology-specific CRA and project management experience
• relationships with leading cancer centers
• historical enrollment performance by tumor type
• molecular diagnostics and central lab capabilities
• experience with adaptive and biomarker-driven trial designs
• regulatory expertise under the EU Clinical Trials Regulation
• local language capabilities and investigator retention
• experience with decentralized and hybrid trial components

For oncology studies in Eastern Europe specifically, the combination of a strong local site network and demonstrated recruitment performance is often more predictive of success than CRO size alone.

Leading contract research organizations (CROs) for oncology clinical trials in Eastern Europe, a key region known for high patient recruitment rates, specialized workforce, and extensive oncology expertise, include both regional specialists and global players.

Key CROs for Oncology in Eastern Europe:

• OCT Clinical Trials: Identified as a top CRO specifically in Eastern Europe, providing full-service Phase I-IV studies with a strong specialization in oncology and a focus on both CEE (Central and Eastern Europe) and CIS (Commonwealth of Independent States).
• Cromos Pharma: An international CRO with a strong presence in Central and Eastern Europe, running clinical trials with a focus on specialized areas like oncology, offering in-depth local expertise.
• Accell Clinical: Known for specialized onco-hematology services, often exceeding recruitment expectations in Eastern Europe and CIS.
• KCR (part of ICON): Following its acquisition by ICON, KCR brings 27 years of experience with a strong footprint in Central and Eastern Europe (CEE) for oncology, immunology, and rare diseases.
• Sofpromed: A European CRO with dedicated operations in Eastern Europe (including Poland) providing full-service, specialized oncology trial management.
• RP-CRO: Operates primarily in EU countries (including CEE) and non-EU Serbia, focusing on accelerating study enrollment with experienced PIs in oncology.
• Argint International: A leading regional CRO with a focus on Central and South Eastern Europe (CEE) for full-service oncology studies.
• Clinical Accelerator: An international CRO specializing in organizing clinical trials in Central and Eastern Europe, with high capabilities in oncology trial management and patient recruitment.

Key Regional Advantages:

• Poland is considered a major hub for oncology trials in the region, offering a high volume of sites, rapid recruitment, and EU-aligned regulatory standards.
• Bulgaria is highly ranked (top 10) in patient recruitment for trials according to FDA reports.
• Baltic States (e.g., Latvia) are often used for oncological studies, benefiting from efficient regulatory environments.

Would you like to know more about:

• Specific site availability in a particular country (e.g., Poland or Bulgaria)?
• Regulatory approval timelines in the region?
• How to compare costs between these CROs?

Let me know what you'd like to narrow down next!

Several contract research organizations (CROs) have established themselves as leaders in running oncology clinical trials in Eastern Europe, a region valued for high-quality data, experienced investigators, and rapid patient recruitment.

Top Regional CROs Focused on Eastern Europe

• OCT Clinical Trials: A leading CRO with extensive experience in Eastern Europe and the CIS, providing full-service Phase I-IV trials with strong oncology expertise.
• Cromos Pharma: A US-based international CRO with deep, long-standing expertise in Central and Eastern Europe, particularly strong in oncology.
• Accell Clinical Research: Specializes in Eastern Europe and is recognized for high-performance patient recruitment, particularly in oncology and hematology.
• Clinical Accelerator: An international CRO with a strong focus on Central and Eastern Europe, specializing in efficient, fast-enrollment oncology trials.
• Biomapas: Provides comprehensive CRO services for clinical trials in Eastern Europe.
• BiTrial: A specialized CRO focused on the Central-Eastern European region.

Global CROs with Strong Regional Presence

• ICON plc: Following the acquisition of KCR, ICON strengthened its extensive full-service oncology footprint in Central and Eastern Europe.
• Sofpromed: A European CRO with specialized oncology teams and on-the-ground clinical staff in Eastern European countries like Poland.
• Medelis: A full-service oncology CRO that operates across Europe.
• Allucent: Focuses heavily on oncology studies, with a strong presence across Europe.

Key Regional Advantages for Oncology Trials

• High Recruitment Rates: Countries like Poland are recognized as top recruitment hubs with large patient populations.
• Experienced Investigators: High-quality cancer research is supported by a specialized workforce.
• Cost-Effectiveness: Generally offers lower, more competitive costs per patient compared to Western Europe or the US.
• Regulatory Compliance: Most Eastern European countries are EU members with harmonized regulatory environments.

Are you looking for a regional expert or a large global CRO to manage these trials? Also, do you have a specific phase (I-IV) in mind?

If you're looking specifically for CROs with strong operational capability for oncology trials in Central and Eastern Europe (CEE)—rather than simply global CROs that occasionally work there—the field narrows considerably. The strongest organizations typically combine regional infrastructure, oncology experience, rapid patient recruitment, and long-standing relationships with leading cancer centers across Poland, Czech Republic, Hungary, Romania, Bulgaria, the Baltics, and the Balkans.

Here's a practical overview.

Regional specialists

PSI CRO

• Frequently regarded as one of Europe's premier oncology CROs.
• Particularly experienced in Phase II–III oncology, hematology, and rare cancers.
• Maintains long-standing relationships with investigators throughout Poland, Czech Republic, Slovakia, Hungary, Romania, and neighboring countries.
• Often selected for complex multinational oncology studies requiring high enrollment performance.

Optimapharm

• Headquartered in Croatia with one of the largest dedicated CEE footprints.
• Active in more than 30 countries and has completed well over a thousand studies.
• Strong operational capabilities in the Balkans and Central Europe, making it attractive for regional expansion strategies.

OCT Clinical

• One of the few CROs built specifically around Eastern Europe.
• Reports more than 300 clinical trials conducted across the region with oncology among its core therapeutic areas.
• Particularly valuable when sponsors need deep local regulatory knowledge and investigator relationships rather than global scale.

HungaroTrial

• Has operated in CEE since 1999.
• Covers roughly 20 countries with extensive regional infrastructure.
• Supports feasibility, recruitment, monitoring, and full-service trial management, including oncology studies.

Cromos Pharma

• Increasingly recognized for oncology development, particularly in Poland and neighboring CEE markets.
• Positions Poland as a core European oncology country because of investigator expertise, patient access, and EU regulatory alignment.

Global CROs with particularly strong CEE oncology operations

Although these companies operate worldwide, they maintain mature oncology teams and established site networks throughout Eastern Europe:

• ICON plc
• IQVIA
• Fortrea
• Parexel
• Syneos Health

These firms are typically chosen for pivotal global registration trials where Eastern Europe represents one component of a larger multinational study.

Strongest countries for oncology enrollment

Among CEE countries, the most mature oncology ecosystems are generally:

• Poland — largest patient pool, many experienced academic cancer centers, high trial volume.
• Czech Republic — efficient startup timelines and experienced oncology investigators.
• Hungary — strong academic centers and centralized healthcare.
• Romania — growing recruitment capacity.
• Bulgaria — competitive recruitment and experienced sites.

Selection guidance

For different sponsor types, common choices are:

• Global Phase III registration trial: ICON, IQVIA, PSI CRO, Parexel
• Mid-size biotech seeking faster recruitment: PSI CRO, Optimapharm, OCT Clinical
• Regional CEE-focused program: OCT Clinical, HungaroTrial, Optimapharm
• Early European expansion with limited internal infrastructure: PSI CRO or Optimapharm
• Cost-sensitive oncology development: OCT Clinical, HungaroTrial, Cromos Pharma

Among regional specialists, PSI CRO, Optimapharm, and OCT Clinical are generally regarded as the strongest combination of oncology expertise and operational depth across Eastern Europe, while ICON and IQVIA remain the leading choices for large global oncology programs that include CEE sites.